2019
Lease space in a business incubator
Fecula Biotechnology Co., Ltd. established.
Our Company
Fecula Biotech focuses on the development of new cancer drugs, utilizing intestinal bacterial extracellular vesicles as a novel drug delivery vehicle. With its independently developed genetic engineering platform and resistant starch encapsulation technology, the company is developing broad-spectrum injectable and oral cancer therapeutic vaccines. The initial research and development primarily targets gastrointestinal cancers, including pancreatic cancer, liver cancer, and colorectal cancer.
The powerful extracellular vesicle drug development technology is not only applicable to the development of new cancer drugs for humans but also suitable for the development and application of preventive vaccines for infectious diseases in livestock and pets.
The powerful extracellular vesicle drug development technology is not only applicable to the development of new cancer drugs for humans but also suitable for the development and application of preventive vaccines for infectious diseases in livestock and pets.
Milestone & Recognitions
Start-up
設立
February 2019
Headquarters
總部
Tainan Science Park Incubation Center
Staff
團隊
7 - PhD: 4; Master's/Bachelor's: 3
Capital
資本額
NT$45 million / National Development Fund: 16%
R&D team
-
Chen ZhimingChairman
Graduated from the Ph.D. program at the Institute of Biotechnology, National Chung Hsing University.
Former General Manager of Guoding Biotechnology Co., Ltd.Development
Molecular biology, small-molecule drug development, clinical trial design and execution, PIC/S cGMP plant management, FDA orphan drug designation applications, and pharmaceutical licensing negotiations. -
Ye JinxingChief Technology Officer
Graduated from the Ph.D. program at the Institute of Biotechnology, National Chung Hsing University.
RA Manager, HealthynBio Co., Ltd.Development
Molecular biology, small-molecule drug development, clinical trial design and execution, PIC/S cGMP facility management, FDA orphan drug designation applications, and pharmaceutical licensing negotiations. -
Wang RuilingR&D chief
Graduated from the Ph.D. program in Physiology at National Yang Ming University.
Associate Researcher, National Laboratory Animal Center.Development
Molecular biology, small-molecule drug development, clinical trial design and execution, PIC/S cGMP facility management, FDA orphan drug designation applications, and pharmaceutical licensing negotiations. -
Huang ShihongR&D Director
Graduated from the Ph.D. program of the Institute of Biochemistry at Chaoyang University of Technology.
Associate Researcher, Taiwan Banana Research Institute.Development
R&D
Partners and Collaborations
-
Chen ShuitianPhD in Biochemistry
Chairman, Haofeng Biotech.
Research Fellow, Institute of Biochemistry and Molecular Biology, Academia Sinica.Development
-
Wu ShenghuaPhD in Microbiology
Chairman, Huaxun Biomedicine.
Researcher, National Museum of Natural Science.Development
-
Wu ShixinPhD in Biotechnology
Professor, Institute of Biomedical Science, China Medical University.
Researcher, Saiya Gene.Development
-
Qiu YihanPhD in Biotechnology
Assistant Professor of Microbiology, Soochow University.
Associate Researcher, ScinoPharm Biotech.Development
Company introduction video
© Fecula Biotech. All Rights Reserved.
Website constructed by
澄交生技 Fecula Biotech
06-505-0511
service@fecula.com.tw
4 F.-1A, No. 25, Nanke 3rd Rd., Xinshi Dist., Tainan City 744094, Taiwan (R.O.C.)